Sales rise 69.79% to Rs 280.76 crore
Posts in category Business Standard
Gujarat Intrux standalone net profit rises 68.83% in the June 2024 quarter (29-07-2024)
Sales rise 20.95% to Rs 15.59 crore
Market Creators reports standalone net profit of Rs 0.10 crore in the June 2024 quarter (29-07-2024)
Sales rise 66.67% to Rs 1.90 crore
Qgo Finance standalone net profit rises 70.59% in the June 2024 quarter (29-07-2024)
Sales rise 24.85% to Rs 4.12 crore
T. Spiritual World reports standalone net loss of Rs 0.09 crore in the June 2024 quarter (29-07-2024)
Reported sales nil
Whirlpool of India consolidated net profit rises 92.07% in the June 2024 quarter (29-07-2024)
Sales rise 22.48% to Rs 2496.86 crore
Sumitomo Chemical Q1FY25 profit more than doubles; stock hits 52-week high (29-07-2024)
The share price soared after the company posted healthy numbers in the June quarter of financial year 2025 (Q1FY25).
EID Parry stock hits new high; soars 10% on hopes of improved profitability (29-07-2024)
EID Parry in its FY24 annual report said, operating profitability is expected to improve in FY25 and would remain rangebound, due to better profitability from sugar business.
India’s biggest 2024 IPOs as stock markets boom: All you need to know (29-07-2024)
More than 150 companies have raised nearly $5 billion through IPOs between January and July
Senores Pharma files IPO with Sebi, aims to raise Rs 500 cr via fresh issue (29-07-2024)
Senores Pharmaceuticals Ltd has filed preliminary papers with capital markets regulator Sebi to raise funds through an initial public offering (IPO).
The Ahmedabad-based company’s IPO is a combination of fresh issuance of shares worth Rs 500 crore and an offer for sale (OFS) of up to 27 lakh equity shares by promoters and other selling shareholders, according to the draft red herring prospectus (DRHP).
The offer also includes a reservation for a subscription by eligible employees.
The pharma company may consider raising up to Rs 100 crore as pre-IPO placement. If such placement is completed, the fresh issue size will be reduced.
Proceeds from its fresh issuance will be utilised for setting up a manufacturing facility for the production of sterile injections in its Atlanta facility; funding the working capital requirements of the company and its subsidiaries; supporting inorganic growth through acquisition and other strategic initiatives and payment of debt. Besides, a portion will